Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

By M. Feldmann, R. Maini. Annual Review of Immunology, 2001

1,306 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4a7ed1a9e984443d2a95f931f703ecaefb5821e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Radiology, Nuclear Medicine and Imaging

In Rheumatology

Citations in the corpus

OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding. (2010, background): “Medicinally, they are a profitable drug class, with the five top-selling antibodies [Rituxan (Plosker and Figgitt, 2003), Remicade (Feldmann and Maini, 2001), Herceptin (Vogel et al., 2001), Humira (Kempeni, 1999) and Avastin (Chen et al., 2001)] having revenues in excess of $11 billion in 2006…”
How can immunology contribute to the control of tuberculosis? (2001, background): “tuberculosis in humans was notably shown by the increased risk of reactivation of tuberculosis in rheumatoid arthritis patients who were undergoing anti-TNF-α therap”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, result): “Many of the published studies on the effects of TNF antagonists on inflammation in humans have been conducted with infliximab-treated patients with RA (reviewed in Feldmann & Maini, 2001; Maini & Feldmann, 2002), and similar results have been observed with etanercept and adalimumab.”
Angiogenesis in rheumatoid arthritis (2002, background): “From the earliest trials in 1992, infliximab has shown remarkable therapeutic efficacy, reducing both clinical and laboratory indices of disease activity (reviewed [46,47]).”
Evolving concepts of rheumatoid arthritis (2003, background): “The mechanism of anti-TNF-α action in vivo is complex and probably includes suppression of other pro-inflammatory cytokines, decreased synovial cellular infiltration, interference with osteoclast activation, and decreased angiogenesi”
Type I interferon in systemic lupus erythematosus and other autoimmune diseases. (2006, background): “Indeed, the clinical success of TNF antagonists demonstrate that TNF plays a critical role in the pathogenesis of diseases such as rheumatoid arthritis and psoriasis (Feldmann and Maini, 2001).”
Development of anti-TNF therapy for rheumatoid arthritis (2002, background): “Part of that effect is due to a reduction of the immunogenicity of anti-TNF antibody, as judged by the reduced response to the chimeric antibod”
NF-κB signaling in inflammation (2017, positive): “85 NF-κ NF-κ B mediates the induction of pro-inflammatory cytokines, such as TNF-α , IL-1 and IL-6, in monocytes/ macrophages.”